Genomic features: Impact on pathogenesis and treatment of chronic lymphocytic leukemia

Oncology Research and Treatment

Volumn 39, Issue 1-2, 2016, Pages 34-40

  Tausch, Eugen ^a   Mertens, Daniel ^a,b   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chronic lymphocytic leukaemia; Cytogenetics; Gene mutations; Prognostic factors

Indexed keywords

ATM PROTEIN; CD20 ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; NOTCH1 RECEPTOR; PROTEIN P53; SPLICING FACTOR 3 SUBUNIT 1 PROTEIN; UNCLASSIFIED DRUG; GENETIC MARKER; TUMOR MARKER; TUMOR PROTEIN;

CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DNA DAMAGE; GENE MUTATION; GENETIC MARKER; GENOMIC INSTABILITY; GENOMICS; HUMAN; HUMAN GENOME; LEUKEMOGENESIS; MONOCLONAL B CELL LYMPHOCYTOSIS; REVIEW; TUMOR GROWTH; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; EVIDENCE-BASED MEDICINE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM PROTEINS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84959252774     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000443906     Document Type: Review

References (50)

1. Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
3. Stilgenbauer S, Schnaiter A, Paschka P, et al.: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123: 3247-3254.
4. Wierda WG, O'Brien S, Wang X, et al.: Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 4088-4095.
5. Byrd JC, Jones JJ, Woyach JA, et al.: Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol Off J Am Soc Clin Oncol 2014; 32: 3039-3047.
6. Landau DA, Tausch E, Taylor-Weiner AN, et al.: Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525-530.
7. Puente XS, Beá S, Valdés-Mas R, et al.: Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526: 519-524.
8. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
9. Kröber A, Seiler T, Benner A, et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
10. Pepper C, Majid A, Lin TT, et al.: Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2012; 156: 499-507.
11. Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
12. Dühren-von Minden M, Übelhart R, Schneider D, et al.: Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309-312.
13. Byrd JC, Furman RR, Coutre SE, et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
14. Furman RR, Sharman JP, Coutre SE, et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
15. Roberts AW, Ma S, Brander D, et al. Venetoclax (ABT-199/ GDC-0199) combined with rituximab induces deep responses in patients with relapsed/refractory chronic lymphocytic leukemia. EHA Ann Meet 2015;abstr S431.
16. Ghia P, Stamatopoulos K, Belessi C, et al.: Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005; 105: 1678-1685.
17. Wan Y, Wu CJ: SF3B1 mutations in chronic lymphocytic leukemia. Blood 2013; 121: 4627-4634.
18. Fazi C, Scarfò L, Pecciarini L, et al.: General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 2011; 118: 6618-6625.
19. Cimmino A, Calin GA, Fabbri M, et al.: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005; 102: 13944-13949.
20. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
21. Dicker F, Herholz H, Schnittger S, et al.: The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2008; 23: 117-124.
22. Thompson PA, O'Brien SM, Wierda WG, et al.: Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinibbased regimens. Cancer 2015; 121: 3612-3621.
23. Edelmann J, Holzmann K, Miller F, et al.: High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012; 120: 4783-4794.
24. Gonzalez D, Martinez P, Wade R, et al.: Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol Off J Am Soc Clin Oncol 2011; 29: 2223-2229.
25. Zenz T, Eichhorst B, Busch R, et al.: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2010; 28: 4473-4479.
26. Eichhorst B, Dreyling M, Robak T, et al.; on behalf of the ESMO Guidelines Working Group: Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22:vi50-vi54.
27. Fabbri G, Rasi S, Rossi D, et al.: Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208: 1389-1401.
28. Landau DA, Carter SL, Stojanov P, et al.: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
29. Quesada V, Conde L, Villamor N, et al.: Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012; 44: 47-52.
30. Wang L, Lawrence MS, Wan Y, et al.: SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
31. Baliakas P, Hadzidimitriou A, Sutton L-A, et al.: Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015; 29: 329-336.
32. Jeromin S, Weissmann S, Haferlach C, et al.: SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 2014; 28: 108-117.
33. Rossi D, Rasi S, Fabbri G, et al.: Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
34. Rossi D, Bruscaggin A, Spina V, et al.: Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011; 118: 6904-6908.
35. Schnaiter A, Paschka P, Rossi M, et al.: NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013; 122: 1266-1270.
36. Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet Lond Engl 2007; 370: 230-239.
37. Papaemmanuil E, Cazzola M, Boultwood J, et al.: Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395.
38. Furney SJ, Pedersen M, Gentien D, et al.: SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013; 3: 1122-1129.
39. Te Raa GD, Derks IA, Navrkalova V, et al.: The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia 2015; 29: 1133-1142.
40. Oscier DG, Rose-Zerilli MJJ, Winkelmann N, et al.: The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468-475.
41. Puente XS, Pinyol M, Quesada V, et al.: Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101-105.
42. Villamor N, Conde L, Martínez-Trillos A, et al.: NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-1106.
43. Weissmann S, Roller A, Jeromin S, et al.: Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 2013; 27: 2393-2396.
44. Tausch E, Schlenk RF, Kless S, et al.: NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study complement 1 (OMB110911). Blood 2013; 122: 527-527.
45. Skowronska A, Parker A, Ahmed G, et al.: Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol Off J Am Soc Clin Oncol 2012; 30: 4524-4532.
46. Rossi D, Fangazio M, Rasi S, et al.: Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862.
47. Rose-Zerilli MJJ, Forster J, Parker H, et al.: ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Haematologica 2014; 99: 736-742.
48. Damm F, Mylonas E, Cosson A, et al.: Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014; 4: 1088-1101.
49. Rossi D, Rasi S, Spina V, et al.: Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403-1412.
50. Pflug N, Bahlo J, Shanafelt TD, et al.: Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124: 49-62.